Aβ1-42/Aβ1-40/T-Tau/p-Tau-181/α-synuclein Multiplex Detection Kit (Flow Cytometry)
Registration Certificate Number20232400002
Aβ1-42, Aβ1-40, p-Tau-181, and α-synuclein levels
Patients in neurology/neuroscience, geriatrics, rehabilitation, physical examination departments, etc.
Alzheimer's disease multi indicator joint testing reagent
Requires only 25 μL of sample, simultaneously detects multiple Alzheimer's disease (AD) biomarkers, including Aβ1-42, Aβ1-40, p-Tau-181, and α-synuclein.
Based on flow cytometry technology, it offers superior performance, accurate results, high sensitivity, and easy operation.
Open reagent platform with low testing investment
1) Early screening and diagnosis of Alzheimer's disease (AD): Detecting peripheral blood biomarkers can identify corresponding pathological changes before clinical symptoms manifest, thereby aiding in the early screening of AD and providing an opportunity for timely intervention;
2) Assessment related to AD treatment: Following targeted drug therapy or other related treatments, the combined detection of peripheral blood biomarkers allows for dynamic monitoring of the treatment's effectiveness and prognosis in AD patients;
3) Primary healthcare: Combined with health checkups, elderly individuals can undergo regular annual screening and receive early intervention.
